10 August, 2023

Towards a deeper understanding of endometriosis

Decades of relative inactivity and limited innovation have characterized a condition often labeled as "enigmatic." In her Guardian article, Gabrielle Jackson sheds light on the newfound optimism emerging from a deeper comprehension of this debilitating, chronic inflammatory disease.

Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment

20 January, 2025

Women's health research funding falls short: A call for change

2 January, 2025

Green innovation: Gesynta's commitment to sustainability

27 November, 2024

Empowering Women's Health: Meet the Artemis Foundation

22 November, 2024

Learn more about Gesynta Pharma

Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our management

The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.

Endometriosis

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our portfolio

Our lead drug candidate vipoglanstat is in clinical phase II for endometriosis, while GS-073 is ready to enter clinical phase I for chronic inflammatory pain.